Specialty CROs Market: Industry Trends and Global Forecasts - Distribution by Target Therapeutic Area, Type of Service and Key Geographical Regions

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. History
• 3.2. Traditional Contract Research Organizations
  • 3.2.1. Services
  • 3.2.2. Current Industry Environment
• 3.3. Specialty Contract Research Organizations

4. SPECIALTY CROs: AN INTRODUCTION

• 4.1. Chapter Overview
• 4.2. Importance of Specialty CROs

5. MARKET OVERVIEW

• 5.1. Chapter Overview
• 5.2. Methodology
• 5.3. Specialty CROs: Global Landscape
  • 5.3.1. Specialty CROs: The Dramatic Rise
  • 5.3.2. Specialty CROs: Distribution by Nature of Specialization
• 5.4. Specialty CROs Focused on Specific Service Capability
  • 5.4.1. Landscape is Well Distributed across Preclinical and Clinical Services
  • 5.4.2. Specialty CROs: Popular Preclinical Services
  • 5.4.3. Specialty CROs: Popular Clinical Services
• 5.5. Specialty CROs Focused on Specific Therapeutic Area(s)
  • 5.5.1. Oncology is the Most Researched Therapeutic Area
  • 5.5.2. CROs Mostly Located in the US; Europe is a Distant Second

6. SPECIALTY CROs: FOCUSED ON SERVICES

• 6.1. Chapter Overview
• 6.2. CROs Focused on Preclinical Service Capabilities
  • 6.2.1. BRI Biopharmaceutical Research
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Focused Clinical Expertise
      • 6.2.1.2.1. API / Clinical Product QC, Dosing Solutions & Materials
      • 6.2.1.2.2. Bioanalytical Assays for Clinical Trials
      • 6.2.1.2.3. Clinical Trial Equipment Rental & PK Sample Collection Kit
      • 6.2.1.2.4. Cynomologus & Rhesus Monkey Hepatocytes & Blood Products
      • 6.2.1.2.5. Drug Candidate Early In Vitro & In Vivo Screening
      • 6.2.1.2.6. In Vitro DMPK & ADME
      • 6.2.1.2.7. In Vivo DMPK & ADME
      • 6.2.1.2.8. Patient Tumor-Derived Xenograft Models at Oncograph(TM)
      • 6.2.1.2.9. Strategic Development of Botanical Drugs
  • 6.2.2. BTS Research
    • 6.2.2.1. Company Overview
    • 6.2.2.2. Focused Clinical Expertise
      • 6.2.2.2.1. Custom Services
      • 6.2.2.2.2. Disease Models
      • 6.2.2.2.3. In Vitro Services
      • 6.2.2.2.4. IND Process
      • 6.2.2.2.5. Medical Devices
      • 6.2.2.2.6. Pharmacology Services
      • 6.2.2.2.7. Toxicology Services
    • 6.2.2.3. Additional Information
      • 6.2.2.3.1. Recent Developments
      • 6.2.2.3.2. Acquisitions
  • 6.2.3. Dorizoe Lifesciences
    • 6.2.3.1. Company Overview
    • 6.2.3.2. Focused Clinical Expertise
      • 6.2.3.2.1. Services and Capabilities
      • 6.2.3.2.2. Customized Services
  • 6.2.4. Fluofarma
    • 6.2.4.1. Company Overview
    • 6.2.4.2. Focused Clinical Expertise
      • 6.2.4.2.1. Assay Development Services
      • 6.2.4.2.2. Cell-based screening services
      • 6.2.4.2.3. In Vitro Drug Profiling Services and Mechanism of Action (MOA) Studies
      • 6.2.4.2.4. Predictive Toxicology Services
      • 6.2.4.2.5. In Vivo Studies
      • 6.2.4.2.6. Biomarker Analysis Services
    • 6.2.4.3. Additional Information
      • 6.2.4.3.1. Collaborations
      • 6.2.4.3.2. Recent Developments
  • 6.2.5. KIYATEC
    • 6.2.5.1. Company Overview
    • 6.2.5.2. Focused Clinical Expertise
      • 6.2.5.2.1. Drug Response Profiling (DRP) Services
    • 6.2.5.3. Additional Information
      • 6.2.5.3.1. Recent Developments
      • 6.2.5.3.2. Funding
  • 6.2.6. Redoxis
    • 6.2.6.1. Company Overview
    • 6.2.6.2. Focused Clinical Expertise
      • 6.2.6.2.1. In Vivo Models
      • 6.2.6.2.2. In Vitro Services
    • 6.2.6.3. Additional Information
      • 6.2.6.3.1. Collaborations
      • 6.2.6.3.2. Recent Developments
      • 6.2.6.3.3. Funding
  • 6.2.7. Spirovation
    • 6.2.7.1. Company Overview
    • 6.2.7.2. Focused Clinical Expertise
      • 6.2.7.2.1. Clinical Assessment
      • 6.2.7.2.2. Functional Screening and Lead Selection
      • 6.2.7.2.3. Target ID and Primary Screening
    • 6.2.7.3. Additional Information
      • 6.2.7.3.1. Facilities
  • 6.2.8. Velesco Pharmaceutical Services
    • 6.2.8.1. Company Overview
    • 6.2.8.2. Focused Clinical Expertise
      • 6.2.8.2.1. Analytical Method Development
      • 6.2.8.2.2. cGMP Manufacturing
      • 6.2.8.2.3. Drug Formulation Development
      • 6.2.8.2.4. Instrumentation
      • 6.2.8.2.5. Pharmaceutical Consulting
• 6.3. CROs Focused on Clinical Service Capabilities
  • 6.3.1. Almedis
    • 6.3.1.1. Company Overview
    • 6.3.1.2. Focused Clinical Expertise
      • 6.3.1.2.1. Biostatistics
      • 6.3.1.2.2. Clinical Monitoring
      • 6.3.1.2.3. International Clinical Trials
      • 6.3.1.2.4. Local Studies
      • 6.3.1.2.5. Data Management
      • 6.3.1.2.6. Medical Writing
      • 6.3.1.2.7. Training Programs
  • 6.3.2. Applied Healthcare Resource Management
    • 6.3.2.1. Company Overview
    • 6.3.2.2. Focused Clinical Services
    • 6.3.2.3. Additional Information
      • 6.3.2.3.1. Collaborations
  • 6.3.3. CMX Research
    • 6.3.3.1. Company Overview
    • 6.3.3.2. Focused Clinical Expertise
      • 6.3.3.2.1. CRO Services
      • 6.3.3.2.2. Investigator Network
      • 6.3.3.2.3. Investigator-Led Trials (ILTs)
      • 6.3.3.2.4. MDapps(TM)
  • 6.3.4. DSP Clinical Research
    • 6.3.4.1. Company Overview
    • 6.3.4.2. Focused Clinical Expertise
      • 6.3.4.2.1. Data Management
      • 6.3.4.2.2. Monitoring
      • 6.3.4.2.3. Project Management
      • 6.3.4.2.4. Site Management
      • 6.3.4.2.5. Statistics and Medical Writing
      • 6.3.4.2.6. Others
    • 6.3.4.3. Additional Information
      • 6.3.4.3.1. Collaboration
      • 6.3.4.3.2. Recent Developments
  • 6.3.5. DZS Clinical Services
    • 6.3.5.1. Company Overview
    • 6.3.5.2. Focused Clinical Services
      • 6.3.5.2.1. Biostatistics Support and Consulting
      • 6.3.5.2.2. Clinical Data Management
      • 6.3.5.2.3. Clinical Monitoring
      • 6.3.5.2.4. Clinical Project Management
      • 6.3.5.2.5. ClinPlus(R) eClinical Platform
      • 6.3.5.2.6. Customized FSP Models
      • 6.3.5.2.7. DZS Clinical Sourcing and Staffing
      • 6.3.5.2.8. Medical Coding
      • 6.3.5.2.9. Medical Writing
      • 6.3.5.2.10. Statistical Programming and CDISC Implementation
      • 6.3.5.2.11. SOP Authoring
  • 6.3.6. EthosExcel(TM)
    • 6.3.6.1. Company Overview
    • 6.3.6.2. Focused Clinical Expertise
      • 6.3.6.2.1. Clinical Trial Services
      • 6.3.6.2.2. Clinical Trial Resourcing
      • 6.3.6.2.3. Diversity Consulting
      • 6.3.6.2.4. Investigator and Trial Site Facilitation Services
      • 6.3.6.2.5. Site Management
  • 6.3.7. ICRC-Weyer
    • 6.3.7.1. Company Overview
    • 6.3.7.2. Focused Clinical Expertise
      • 6.3.7.2.1. Biostatistics
      • 6.3.7.2.2. Clinical Data Management
      • 6.3.7.2.3. Medical Review
      • 6.3.7.2.4. Medical Writing
      • 6.3.7.2.5. Safety Writing and Pharmacovigilance
      • 6.3.7.2.6. Scientific Consulting
    • 6.3.7.3. Additional Information
      • 6.3.7.3.1. Expansion of Service Portfolio
  • 6.3.8. Impact Pharmaceutical Services
    • 6.3.8.1. Company Overview
    • 6.3.8.2. Focused Clinical Expertise
      • 6.3.8.2.1. Drug Development Consulting
      • 6.3.8.2.2. Early Phase Clinical Trial Management
      • 6.3.8.2.3. Medical Writing
      • 6.3.8.2.4. Project and Program Management
      • 6.3.8.2.5. Regulatory Affairs
      • 6.3.8.2.6. Regulatory Operations
  • 6.3.9. Research Dynamics Consulting
    • 6.3.9.1. Company Overview
    • 6.3.9.2. Focused Clinical Expertise
      • 6.3.9.2.1. Clinical Monitoring
      • 6.3.9.2.2. Consulting
      • 6.3.9.2.3. GCP Auditing
      • 6.3.9.2.4. Investigator Recruitment
      • 6.3.9.2.5. Project Management
      • 6.3.9.2.6. Site Management
    • 6.3.9.3. Additional Information
      • 6.3.9.3.1. Collaborations
  • 6.3.10. SDS Clinical
    • 6.3.10.1. Company Overview
    • 6.3.10.2. Focused Clinical Expertise
      • 6.3.10.2.1. Clinical Trial Services
      • 6.3.10.2.2. Consulting Services

7. SPECIALTY CROs: FOCUSED ON THERAPEUTIC AREAS

• 7.1. Chapter Overview
• 7.2. Specialty CROs Focused on Oncology
  • 7.2.1. Accelovance
    • 7.2.1.1. Company Overview
    • 7.2.1.2. Focused Clinical Expertise
      • 7.2.1.2.1. CRO Services
      • 7.2.1.2.2. Patient Recruitment
      • 7.2.1.2.3. Clinical Call Center
    • 7.2.1.3. Additional Information
      • 7.2.1.3.1. Collaborations
      • 7.2.1.3.2. Site Expansion
  • 7.2.2. Crown Bioscience
    • 7.2.2.1. Company Overview
    • 7.2.2.2. Focused Clinical Expertise
      • 7.2.2.2.1. Biotherapeutics
      • 7.2.2.2.2. Drug Discovery
      • 7.2.2.2.3. Metabolic Diseases
      • 7.2.2.2.4. Oncology
    • 7.2.2.3. Additional Information
      • 7.2.2.3.1. Collaborations
      • 7.2.2.3.2. Service Expansion
      • 7.2.2.3.3. Site Expansion
      • 7.2.2.3.4. Recent Developments
      • 7.2.2.3.5. Funding
  • 7.2.3. MedSource
    • 7.2.3.1. Company Overview
    • 7.2.3.2. Focused Clinical Expertise
      • 7.2.3.2.1. Clinical Data Management and Biostatistics
      • 7.2.3.2.2. Clinical Support
      • 7.2.3.2.3. Clinical Trial Monitoring
      • 7.2.3.2.4. Project Management
      • 7.2.3.2.5. Regulatory Affairs Management
      • 7.2.3.2.6. Study Start-Up
  • 7.2.4. Novella Clinical
    • 7.2.4.1. Company Overview
    • 7.2.4.2. Focused Clinical Expertise
      • 7.2.4.2.1. Clinical Monitoring
      • 7.2.4.2.2. Data Management
      • 7.2.4.2.3. Data Monitoring Committees
      • 7.2.4.2.4. Investigator Strategy & Site Coordination (ISSC)
      • 7.2.4.2.5. Medical Monitoring
      • 7.2.4.2.6. Medical Writing
      • 7.2.4.2.7. Project Management
      • 7.2.4.2.8. Quality Assurance
      • 7.2.4.2.9. Regulatory Affairs
      • 7.2.4.2.10. Safety Management
      • 7.2.4.2.11. Steering Committees & Clinical Advisory Boards
      • 7.2.4.2.12. Training
      • 7.2.4.2.13. Clinical Staffing
      • 7.2.4.2.14. Expertise in Oncology across Various Phases of Clinical Trials
• 7.3. Specialty CROs Focused on Cardiovascular / Cardiology
  • 7.3.1. Cardialysis
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Focused Clinical Expertise
      • 7.3.1.2.1. Trial Services
      • 7.3.1.2.2. Core Laboratory
      • 7.3.1.2.3. Network of Partners
    • 7.3.1.3. Additional Information
  • 7.3.2. IonsGate Preclinical Services
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Focused Clinical Expertise
      • 7.3.2.2.1. Cell Based Assays
      • 7.3.2.2.2. Isolated Tissue Based Assays
      • 7.3.2.2.3. In Vivo Models
• 7.4. Specialty CROs Focused on Metabolic Disorders
  • 7.4.1. Betagenex
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Focused Clinical Expertise
      • 7.4.1.2.1. Experimental Services
      • 7.4.1.2.2. Consulting Services
    • 7.4.1.3. Additional Information
  • 7.4.2. Physiogenex
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Focused Clinical Expertise
      • 7.4.2.2.1. Research Services
      • 7.4.2.2.2. Consultancy Services
    • 7.4.2.3. Additional Information
      • 7.4.2.3.1. Collaborations
      • 7.4.2.3.2. Recent Developments
  • 7.4.3. Profil Institute
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Focused Clinical Expertise
      • 7.4.3.2.1. Clinical Development
      • 7.4.3.2.2. Clinical Research
      • 7.4.3.2.3. Data Management and Statistical Services
      • 7.4.3.2.4. Monitoring, Quality & Compliance
      • 7.4.3.2.5. Recruitment Services
      • 7.4.3.2.6. Regulatory Affairs
      • 7.4.3.2.7. Scientific Services
      • 7.4.3.2.8. Experience in Metabolic Disorders
    • 7.4.3.3. Additional Information
      • 7.4.3.3.1. Collaborations
• 7.5. Specialty CROs Focused on CNS
  • 7.5.1. Biospective
    • 7.5.1.1. Company Overview
    • 7.5.1.2. Focused Clinical Expertise
      • 7.5.1.2.1. Image Processing Technology
      • 7.5.1.2.2. Rodent Models
      • 7.5.1.2.3. Animal Imaging
      • 7.5.1.2.4. Human Imaging and Clinical Trials
      • 7.5.1.2.5. Histology and IHC
  • 7.5.2. RenaSci
    • 7.5.2.1. Company Overview
    • 7.5.2.2. Focused Clinical Expertise
      • 7.5.2.2.1. Experimental Services
      • 7.5.2.2.2. Consultancy Services
    • 7.5.2.3. Additional Information
      • 7.5.2.3.1. Recent Developments
  • 7.5.3. RxGen
    • 7.5.3.1. Company Overview
    • 7.5.3.2. Focused Clinical Expertise
      • 7.5.3.2.1. Efficacy Models
      • 7.5.3.2.2. Custom Model Development
      • 7.5.3.2.3. Pharmacokinetics, Pharmacodynamics and Delivery Optimization Services
      • 7.5.3.2.4. Toxicology and Safety Pharmacology
      • 7.5.3.2.5. Supporting Technologies & Capabilities
    • 7.5.3.3. Additional Information
      • 7.5.3.3.1. Collaboration
      • 7.5.3.3.2. Funding
      • 7.5.3.3.3. Recent Developments

8. CASE STUDY I: VIRTUAL CROs

• 8.1. Introduction to Virtual CROs
• 8.2. Frestedt
  • 8.2.1. Company Overview
  • 8.2.2. Service Portfolio
    • 8.2.2.1. Clinical Research
    • 8.2.2.2. Regulatory Affairs
    • 8.2.2.3. Quality Systems
• 8.3. InSymbiosis
  • 8.3.1. Company Overview
  • 8.3.2. Service Portfolio
    • 8.3.2.1. Drug Discovery
    • 8.3.2.2. Lead Optimization and Efficacy Model
    • 8.3.2.3. Non-Clinical Safety Studies and Bioanalysis
    • 8.3.2.4. Regulatory IND / IMPD filings
    • 8.3.2.5. Document Management
    • 8.3.2.6. Phase I / II/ III Clinical Studies
    • 8.3.2.7. Collaborations
  • 8.3.3. Additional Information
    • 8.3.3.1. Recent Developments
• 8.4. Osiris Pharma
  • 8.4.1. Company Overview
  • 8.4.2. Service Portfolio
    • 8.4.2.1. Program Management
    • 8.4.2.2. Consultancy
    • 8.4.2.3. Non-clinical Assessment and Management
    • 8.4.2.4. Preclinical Toxicology and Safety Studies
    • 8.4.2.5. Communication and Monitoring
    • 8.4.2.6. Writing and Reviewing of Reports
    • 8.4.2.7. Other Services
• 8.5. ProjectPharm
  • 8.5.1. Company Overview
  • 8.5.2. Service Portfolio
    • 8.5.2.1. Virtual CRO
    • 8.5.2.2. Project Management Consulting / Organizational Project Management
    • 8.5.2.3. Vendor Selection
    • 8.5.2.4. Financial Audits
    • 8.5.2.5. Training
    • 8.5.2.6. Rescue Studies
    • 8.5.2.7. Study Start-Up
• 8.6. The Harte Group
  • 8.6.1. Company Overview
  • 8.6.2. Service Portfolio
    • 8.6.2.1. Virtual CRO
    • 8.6.2.2. Consultation
    • 8.6.2.3. Clinical Trial Project Management
    • 8.6.2.4. Integrated Project Delivery and Accountability
• 8.7. VxP Pharma
  • 8.7.1. Company Overview
  • 8.7.2. Service Portfolio
    • 8.7.2.1. Chemical Development
    • 8.7.2.2. Preclinical
    • 8.7.2.3. Preformulation and Solid State Chemistry
    • 8.7.2.4. Analytical and Bioanalytical
      • 8.7.2.4.1. Analytical Method Development and Validation
      • 8.7.2.4.2. Extractables and Leachables Studies
      • 8.7.2.4.3. Particle Size Determination
      • 8.7.2.4.4. Container-API Compatibility
      • 8.7.2.4.5. Material Characterization
      • 8.7.2.4.6. Forced Degradation and Stability Studies
      • 8.7.2.4.7. Drug Device Compatibility Studies
      • 8.7.2.4.8. Microbial Testing
      • 8.7.2.4.9. Bioanalytical Testing
    • 8.7.2.5. Formulation Development and Clinical Trial materials
    • 8.7.2.6. Parenteral and Lyophilized Clinical Trial Materials
    • 8.7.2.7. Clinical Packaging and Distribution
    • 8.7.2.8. Commercial Services

9. CASE STUDY II: FULL SERVICE CROs

• 9.1. Introduction to Traditional CROs
• 9.2. Covance
  • 9.2.1. Company Overview
  • 9.2.2. Service Portfolio
    • 9.2.2.1. Analytical Services
    • 9.2.2.2. Clinical Development
    • 9.2.2.3. Clinical Testing
    • 9.2.2.4. Consulting
    • 9.2.2.5. Health Economics & Market Access
    • 9.2.2.6. Lead Optimization
    • 9.2.2.7. Manufacturing Services
    • 9.2.2.8. Research
    • 9.2.2.9. Safety Assessment
  • 9.2.3. Collaborations
• 9.3. Medis Research Group
  • 9.3.1. Company Overview
  • 9.3.2. Focused Clinical Expertise
    • 9.3.2.1. Biostatistics
    • 9.3.2.2. Data Management
    • 9.3.2.3. Medical Writing
    • 9.3.2.4. Oncology Expertise
    • 9.3.2.5. Pharmacovigilance
    • 9.3.2.6. Proofreading and Translation
    • 9.3.2.7. RDC System ODM QuaSi(R)
    • 9.3.2.8. Regulatory Services
    • 9.3.2.9. Scientific Consulting
    • 9.3.2.10. Study Documentation
    • 9.3.2.11. Study Management
    • 9.3.2.12. Study Monitoring
    • 9.3.2.13. Clinical Trial Phase Expertise
    • 9.3.2.14. Additional Information
• 9.4. Quintiles
  • 9.4.1. Company Overview
  • 9.4.2. Service Portfolio
    • 9.4.2.1. Clinical Trial Execution
    • 9.4.2.2. Consulting
    • 9.4.2.3. Laboratories
    • 9.4.2.4. Real-World and Late Phase
    • 9.4.2.5. Patient and Provider Engagement
    • 9.4.2.6. Product Marketing and Sales
    • 9.4.2.7. Technology Solutions
    • 9.4.2.8. Portfolio and Strategic Planning
  • 9.4.3. Financial Performance
  • 9.4.4. Collaborations
  • 9.4.5. Recent Developments
• 9.5. Triclinium Clinical Trial Project Management
  • 9.5.1. Company Overview
    • 9.5.1.1. Focused Clinical Expertise
    • 9.5.1.2. Additional Information
      • 9.5.1.2.1. Collaborations

10. MARKET FORECAST

• 10.1. Chapter Overview
• 10.2. Forecast Methodology
• 10.3. Global Specialty CROs Market, Till 2035
• 10.4. Regional Specialty CROs Market, Till 2035

11. FUTURE OPPORTUNITIES

• 11.1. Chapter Overview
• 11.2. The Changing Scenario of Outsourcing
• 11.3. Health Economics and Outcomes Research (HEOR) Studies
• 11.4. Adaptive Trial Design
• 11.5. eClinical Solutions
• 11.6. Risk Based Monitoring (RBM)
• 11.7. Digital CRO (dCRO)

12. CONCLUSION

• 12.1. A Widening Portfolio of Services Governed by Industry Constraints
• 12.2. Closer Working Collaboration is the Key to Success
• 12.3. Within Therapeutic Areas, Oncology is the Flagbearer
• 12.4. Due to Several Niche Offerings, Specialty CRO Market Remains Fragmented
• 12.5. The Market of Specialty CROs is Likely to Sustain the Growth Momentum
• 12.6. Untapped Opportunity Areas will Emerge as Key Growth Drivers in the Long-Term
• 12.7. Concluding Remarks

13. INTERVIEW TRANSCRIPTS

• 13.1. Chapter Overview
• 13.2. President, CRO and Outcomes Research, Company A
• 13.3. President, Company B

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

16. APPENDIX 3: SERVICE MAP GLOSSARY

List of Tables

• Table 5.1 Specialty CROs: Global Landscape
• Table 5.2 List of Specialty CROs and their Service Capabilities
• Table 5.3 Specialty CROs: Classification by Therapeutic Areas
• Table 6.1 BTS Research: Animal Models for Immune and Inflammatory Diseases
• Table 6.2 BTS Research: Animal Models for Oncology
• Table 6.3 BTS Research: Animal Models for CNS
• Table 7.1 Accelovance China: Services
• Table 7.2 MedSource: Research Experience in Oncology by Type of Indication
• Table 7.3 Physiogenex: Animal Models for Diabetes
• Table 7.4 Physiogenex: Technology Platform for Diabetes
• Table 7.5 Physiogenex: Animal Models for Dyslipidemia
• Table 7.6 Physiogenex: Technology Platform for Dyslipidemia
• Table 7.7 Physiogenex: Animal Models for NAFLD/NASH
• Table 7.8 Physiogenex: Technology Platform for NAFLD/NASH
• Table 7.9 Physiogenex: Animal Models for Obesity
• Table 7.10 Physiogenex: Technology Platform for Obesity
• Table 7.11 Physiogenex: Animal Models for Nutraceuticals
• Table 7.12 Physiogenex: Technology Platforms for Nutraceuticals
• Table 8.1 VxP Pharma: Systems Suitable for E/L testing
• Table 14.1 Specialty CROs: Distribution by Year of Foundation
• Table 14.2 Specialty CROs: Distribution by Nature of Specialization
• Table 14.3 Specialty CRO Services: Stage of Development
• Table 14.4 Specialty CROs: Focused Preclinical Services
• Table 14.5 Specialty CROs: Focused Clinical Services
• Table 14.6 Specialty CROs: Distribution by Focused Therapeutic Areas
• Table 14.7 Specialty CROs: Geographical Distribution by Therapeutic Area
• Table 14.8 Novella Clinical: Oncological Trial Experience (%)
• Table 14.9 Quintiles: Service Revenue, Since 2015 (USD Million)
• Table 14.10 Overall Specialty CROs Market, Short-Midterm: Base Scenario (USD Billion)
• Table 14.11 Overall Specialty CROs Market, Long Term Since 2020: Base Scenario (USD Billion)
• Table 14.12 Regional Market Forecast: Base Scenario (USD Billion)
• Table 14.13 Overall Specialty CROs Market, Short-Midterm: Conservative Scenario (USD Billion)
• Table 14.14 Overall Specialty CROs Market, Long Term Since 2020: Conservative Scenario (USD Billion)
• Table 14.15 Regional Market Forecast: Conservative Scenario (USD Billion)
• Table 14.16 Overall Specialty CROs Market, Short-Midterm: Optimistic Scenario (USD Billion)
• Table 14.17 Overall Specialty CROs Market, Long Term Since 2020: Optimistic Scenario (USD Billion)
• Table 14.18 Regional Market Forecast: Optimistic Scenario (USD Billion)
• Table 14.19 Specialty CROs Market: Comparative Market Evolution Scenarios (USD Billion)

List of Figures

• Figure 4.1 Specialty CROs: Benefits
• Figure 4.2 Specialty CROs: Areas of Specialization
• Figure 5.1 Specialty CROs: Distribution on the Basis of Year of Foundation
• Figure 5.2 Specialty CROs: Distribution by Nature of Specialization
• Figure 5.3 Specialty CRO Services: Stage of Development
• Figure 5.4 Specialty CROs: Focused Preclinical Services
• Figure 5.5 Specialty CROs: Focused Clinical Services
• Figure 5.6 Specialty CROs: Distribution by Focused Therapeutic Areas
• Figure 5.7 Specialty CROs: Geographical Distribution by Therapeutic Area
• Figure 6.1 Specialty CROs: Focused Capabilities
• Figure 6.2 BTS Research: Services for Custom Monoclonal and Polyclonal Antibody
• Figure 6.3 Dorizoe Lifesciences: Dosage Forms
• Figure 6.4 Dorizoe Lifesciences: Formulation Development Protocol
• Figure 6.5 Dorizoe Lifesciences: Customized Services
• Figure 6.6 Spirovation: Samples and Biomarkers used for Biomarker Evaluation
• Figure 6.7 Velesco Pharmaceutical Services: Portfolio
• Figure 6.8 ICRC-Weyer: Biostatistical Services
• Figure 6.9 ICRC-Weyer: Safety Writing and Pharmacovigilance
• Figure 6.10 Impact Pharmaceuticals: Medical Writing
• Figure 7.1 Specialty CROs: Focused Therapeutic Area(S)
• Figure 7.2 Novella Clinical: EDC and Supporting Systems
• Figure 7.3 Novella Clinical: Project Management Cycle
• Figure 7.4 Novella Clinical: Oncological Trial Experience (%)
• Figure 7.5 Physiogenex: Preclinical Services for First Level Phenotyping and Screening
• Figure 7.6 Profil Institute: Expertise in Anti-Diabetes Compounds
• Figure 7.7 Profil Institute: Expertise in Anti-Obesity Compounds and Devices
• Figure 7.8 Biospective: Rodent Models
• Figure 7.9 Biospective: Imaging Services For 1.5 and 3T MRI and Brain Pet Studies
• Figure 7.10 Biospective: Therapeutic Areas for Human Imaging
• Figure 7.11 Biospective: Services for Quantitative Image Analysis
• Figure 7.12 Biospective: Stains for Histology and Immunochemistry Studies
• Figure 8.1 Frestedt: Service Portfolio
• Figure 8.2 ProjectPharm: Consulting Services
• Figure 8.3 The Harte Group: Clinical Trial Project Management Services
• Figure 8.4 VxP Pharma: GLP Radiolabelling Studies
• Figure 8.5 VxP Pharma: Mammalian and Viral Cell Banks
• Figure 9.1 Quintiles: Service Revenue (USD Million)
• Figure 10.1 Overall Specialty CROs Market, Short-Midterm: Base Scenario (USD Billion)
• Figure 10.2 Overall Specialty CROs Market, Long Term Since 2020 Base Scenario (USD Billion)
• Figure 10.3 Regional Market Forecast: Base Scenario (USD Billion)
• Figure 11.1 Specialty CROs: Future Opportunities